The clinical trials taken from clinicaltrials.gov using an immune checkpoint inhibitor (CTLA-4, PD-1, TIM-3, LAG-3 or IDO-1) for GBM treatment are included in Table 1. Here, IDO1 is linked to glioblastoma.